Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment

John T. Walkup, Karen Wagner, Leslie Miller, Gayane Yenokyan, Joan L. Luby, Paramjit T. Joshi, David A. Axelson, Adelaide Robb, Jay A. Salpekar, Dwight Wolf, Abanti Sanyal, Boris Birmaher, Benedetto Vitiello, Mark A. Riddle

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective The Treatment of Early Age Mania (TEAM) study evaluated lithium, risperidone, and divalproex sodium (divalproex) in children with bipolar I disorder who were naive to antimanic medication, or were partial or nonresponders to 1 of 3 study medications. This report evaluates the benefit of either an add-on or a switch of antimanic medications for an 8-week trial period in partial responders and nonresponders, respectively. Method TEAM is a randomized, controlled trial of individuals (N = 379) aged 6 to 15 years (mean ± SD = 10.2 ± 2.7 years) with DSM-IV bipolar I disorder (mixed or manic phase). Participants (n = 154) in this report were either nonresponders or partial responders to 1 of the 3 study medications. Nonresponders (n = 89) were randomly assigned to 1 of the other 2 antimanic medications and cross-tapered. Partial responders (n = 65) were randomly assigned to 1 of 2 other antimanic medications as an add-on to their initial medication. Adverse event (AE) rates are reported only for the add-on group. Results Response rate for children switched to risperidone (47.6%) was higher than for those switched to either lithium (12.8%; p =.005; number needed to treat [NNT] = 3; 95% CI = 1.71-9.09) or divalproex (17.2%; p =.03; NNT = 3; 95% CI = 1.79-20.10); response rate for partial responders who added risperidone (53.3%) was higher than for those who added divalproex (0%; p =.0002; NNT = 2; 95% CI = 1.27-3.56) and trended higher for lithium (26.7%; p =.07; NNT = 4). Reported AEs in the add-on group were largely consistent with the known AE profile for the second medication. Weight gain (kg) was observed for all add-on medications: lithium add-on (n = 29 of 30) = 1.66 ± 1.97; risperidone add-on (n = 15 of 15) = 2.8 ± 1.34; divalproex add-on (n = 19 of 20) = 1.42 ± 1.96. There was no evidence at the 5% significance level that the average weight gain was different by study medication for partial responders (p =.07, 1-way analysis of variance). Conclusion Risperidone appears to be more useful than lithium or divalproex for children with bipolar I disorder and other comorbid conditions who are nonresponders or partial responders to an initial antimanic medication trial.

Original languageEnglish (US)
Pages (from-to)1008-1019
Number of pages12
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume54
Issue number12
DOIs
StatePublished - 2015

Fingerprint

Antimanic Agents
Valproic Acid
Bipolar Disorder
Risperidone
Numbers Needed To Treat
Lithium
Weight Gain
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Analysis of Variance
Randomized Controlled Trials

Keywords

  • bipolar
  • mania
  • nonresponders
  • pharmacology
  • treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Treatment of Early-Age Mania : Outcomes for Partial and Nonresponders to Initial Treatment. / Walkup, John T.; Wagner, Karen; Miller, Leslie; Yenokyan, Gayane; Luby, Joan L.; Joshi, Paramjit T.; Axelson, David A.; Robb, Adelaide; Salpekar, Jay A.; Wolf, Dwight; Sanyal, Abanti; Birmaher, Boris; Vitiello, Benedetto; Riddle, Mark A.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 54, No. 12, 2015, p. 1008-1019.

Research output: Contribution to journalArticle

Walkup, JT, Wagner, K, Miller, L, Yenokyan, G, Luby, JL, Joshi, PT, Axelson, DA, Robb, A, Salpekar, JA, Wolf, D, Sanyal, A, Birmaher, B, Vitiello, B & Riddle, MA 2015, 'Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 54, no. 12, pp. 1008-1019. https://doi.org/10.1016/j.jaac.2015.09.015
Walkup, John T. ; Wagner, Karen ; Miller, Leslie ; Yenokyan, Gayane ; Luby, Joan L. ; Joshi, Paramjit T. ; Axelson, David A. ; Robb, Adelaide ; Salpekar, Jay A. ; Wolf, Dwight ; Sanyal, Abanti ; Birmaher, Boris ; Vitiello, Benedetto ; Riddle, Mark A. / Treatment of Early-Age Mania : Outcomes for Partial and Nonresponders to Initial Treatment. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2015 ; Vol. 54, No. 12. pp. 1008-1019.
@article{ce57f5a8cae249cbaf8df5b7fa07b691,
title = "Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment",
abstract = "Objective The Treatment of Early Age Mania (TEAM) study evaluated lithium, risperidone, and divalproex sodium (divalproex) in children with bipolar I disorder who were naive to antimanic medication, or were partial or nonresponders to 1 of 3 study medications. This report evaluates the benefit of either an add-on or a switch of antimanic medications for an 8-week trial period in partial responders and nonresponders, respectively. Method TEAM is a randomized, controlled trial of individuals (N = 379) aged 6 to 15 years (mean ± SD = 10.2 ± 2.7 years) with DSM-IV bipolar I disorder (mixed or manic phase). Participants (n = 154) in this report were either nonresponders or partial responders to 1 of the 3 study medications. Nonresponders (n = 89) were randomly assigned to 1 of the other 2 antimanic medications and cross-tapered. Partial responders (n = 65) were randomly assigned to 1 of 2 other antimanic medications as an add-on to their initial medication. Adverse event (AE) rates are reported only for the add-on group. Results Response rate for children switched to risperidone (47.6{\%}) was higher than for those switched to either lithium (12.8{\%}; p =.005; number needed to treat [NNT] = 3; 95{\%} CI = 1.71-9.09) or divalproex (17.2{\%}; p =.03; NNT = 3; 95{\%} CI = 1.79-20.10); response rate for partial responders who added risperidone (53.3{\%}) was higher than for those who added divalproex (0{\%}; p =.0002; NNT = 2; 95{\%} CI = 1.27-3.56) and trended higher for lithium (26.7{\%}; p =.07; NNT = 4). Reported AEs in the add-on group were largely consistent with the known AE profile for the second medication. Weight gain (kg) was observed for all add-on medications: lithium add-on (n = 29 of 30) = 1.66 ± 1.97; risperidone add-on (n = 15 of 15) = 2.8 ± 1.34; divalproex add-on (n = 19 of 20) = 1.42 ± 1.96. There was no evidence at the 5{\%} significance level that the average weight gain was different by study medication for partial responders (p =.07, 1-way analysis of variance). Conclusion Risperidone appears to be more useful than lithium or divalproex for children with bipolar I disorder and other comorbid conditions who are nonresponders or partial responders to an initial antimanic medication trial.",
keywords = "bipolar, mania, nonresponders, pharmacology, treatment",
author = "Walkup, {John T.} and Karen Wagner and Leslie Miller and Gayane Yenokyan and Luby, {Joan L.} and Joshi, {Paramjit T.} and Axelson, {David A.} and Adelaide Robb and Salpekar, {Jay A.} and Dwight Wolf and Abanti Sanyal and Boris Birmaher and Benedetto Vitiello and Riddle, {Mark A.}",
year = "2015",
doi = "10.1016/j.jaac.2015.09.015",
language = "English (US)",
volume = "54",
pages = "1008--1019",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Treatment of Early-Age Mania

T2 - Outcomes for Partial and Nonresponders to Initial Treatment

AU - Walkup, John T.

AU - Wagner, Karen

AU - Miller, Leslie

AU - Yenokyan, Gayane

AU - Luby, Joan L.

AU - Joshi, Paramjit T.

AU - Axelson, David A.

AU - Robb, Adelaide

AU - Salpekar, Jay A.

AU - Wolf, Dwight

AU - Sanyal, Abanti

AU - Birmaher, Boris

AU - Vitiello, Benedetto

AU - Riddle, Mark A.

PY - 2015

Y1 - 2015

N2 - Objective The Treatment of Early Age Mania (TEAM) study evaluated lithium, risperidone, and divalproex sodium (divalproex) in children with bipolar I disorder who were naive to antimanic medication, or were partial or nonresponders to 1 of 3 study medications. This report evaluates the benefit of either an add-on or a switch of antimanic medications for an 8-week trial period in partial responders and nonresponders, respectively. Method TEAM is a randomized, controlled trial of individuals (N = 379) aged 6 to 15 years (mean ± SD = 10.2 ± 2.7 years) with DSM-IV bipolar I disorder (mixed or manic phase). Participants (n = 154) in this report were either nonresponders or partial responders to 1 of the 3 study medications. Nonresponders (n = 89) were randomly assigned to 1 of the other 2 antimanic medications and cross-tapered. Partial responders (n = 65) were randomly assigned to 1 of 2 other antimanic medications as an add-on to their initial medication. Adverse event (AE) rates are reported only for the add-on group. Results Response rate for children switched to risperidone (47.6%) was higher than for those switched to either lithium (12.8%; p =.005; number needed to treat [NNT] = 3; 95% CI = 1.71-9.09) or divalproex (17.2%; p =.03; NNT = 3; 95% CI = 1.79-20.10); response rate for partial responders who added risperidone (53.3%) was higher than for those who added divalproex (0%; p =.0002; NNT = 2; 95% CI = 1.27-3.56) and trended higher for lithium (26.7%; p =.07; NNT = 4). Reported AEs in the add-on group were largely consistent with the known AE profile for the second medication. Weight gain (kg) was observed for all add-on medications: lithium add-on (n = 29 of 30) = 1.66 ± 1.97; risperidone add-on (n = 15 of 15) = 2.8 ± 1.34; divalproex add-on (n = 19 of 20) = 1.42 ± 1.96. There was no evidence at the 5% significance level that the average weight gain was different by study medication for partial responders (p =.07, 1-way analysis of variance). Conclusion Risperidone appears to be more useful than lithium or divalproex for children with bipolar I disorder and other comorbid conditions who are nonresponders or partial responders to an initial antimanic medication trial.

AB - Objective The Treatment of Early Age Mania (TEAM) study evaluated lithium, risperidone, and divalproex sodium (divalproex) in children with bipolar I disorder who were naive to antimanic medication, or were partial or nonresponders to 1 of 3 study medications. This report evaluates the benefit of either an add-on or a switch of antimanic medications for an 8-week trial period in partial responders and nonresponders, respectively. Method TEAM is a randomized, controlled trial of individuals (N = 379) aged 6 to 15 years (mean ± SD = 10.2 ± 2.7 years) with DSM-IV bipolar I disorder (mixed or manic phase). Participants (n = 154) in this report were either nonresponders or partial responders to 1 of the 3 study medications. Nonresponders (n = 89) were randomly assigned to 1 of the other 2 antimanic medications and cross-tapered. Partial responders (n = 65) were randomly assigned to 1 of 2 other antimanic medications as an add-on to their initial medication. Adverse event (AE) rates are reported only for the add-on group. Results Response rate for children switched to risperidone (47.6%) was higher than for those switched to either lithium (12.8%; p =.005; number needed to treat [NNT] = 3; 95% CI = 1.71-9.09) or divalproex (17.2%; p =.03; NNT = 3; 95% CI = 1.79-20.10); response rate for partial responders who added risperidone (53.3%) was higher than for those who added divalproex (0%; p =.0002; NNT = 2; 95% CI = 1.27-3.56) and trended higher for lithium (26.7%; p =.07; NNT = 4). Reported AEs in the add-on group were largely consistent with the known AE profile for the second medication. Weight gain (kg) was observed for all add-on medications: lithium add-on (n = 29 of 30) = 1.66 ± 1.97; risperidone add-on (n = 15 of 15) = 2.8 ± 1.34; divalproex add-on (n = 19 of 20) = 1.42 ± 1.96. There was no evidence at the 5% significance level that the average weight gain was different by study medication for partial responders (p =.07, 1-way analysis of variance). Conclusion Risperidone appears to be more useful than lithium or divalproex for children with bipolar I disorder and other comorbid conditions who are nonresponders or partial responders to an initial antimanic medication trial.

KW - bipolar

KW - mania

KW - nonresponders

KW - pharmacology

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84961589272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961589272&partnerID=8YFLogxK

U2 - 10.1016/j.jaac.2015.09.015

DO - 10.1016/j.jaac.2015.09.015

M3 - Article

C2 - 26598476

AN - SCOPUS:84961589272

VL - 54

SP - 1008

EP - 1019

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 12

ER -